Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by pelabooston Feb 07, 2024 7:50am

230 Views

Post# 35866929

Morning Thoughts

Yesterday on Fierce Biotech I noticed an article on Roche. I am not suggesting it has anything to do with ONCY, but it is apparent Roche is making a number of changes and it is possible that it suits them to have ONCY set up the Adaptive Phase 3.

I should correct something I said yesterday; if MC has nothing in hand, then it is possible we will face a punish financing not an RS. If we do have the goods I suppose we could survive even that.

In actuality I have no clue what is going on.

later

<< Previous

Bullboard Posts

Next >>

Calibre discovers significant gold in Newfoundland